Bayesian Capital Management LP Reduces Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)
Bayesian Capital Management LP trimmed its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 20.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,674 shares of the biopharmaceutical company’s stock after selling 8,000 shares during the […]
More Stories
Endava (NYSE:DAVA) Updates FY 2025 Earnings Guidance
Endava (NYSE:DAVA – Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company...
MillerKnoll (NASDAQ:MLKN) Updates FY 2025 Earnings Guidance
MillerKnoll (NASDAQ:MLKN – Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company...
UMB Financial Co. (NASDAQ:UMBF) Given Average Rating of “Buy” by Brokerages
Shares of UMB Financial Co. (NASDAQ:UMBF – Get Free Report) have earned an average rating of “Buy” from the six...
Brokerages Set Air Transport Services Group, Inc. (NASDAQ:ATSG) Price Target at $21.67
Air Transport Services Group, Inc. (NASDAQ:ATSG – Get Free Report) has received an average rating of “Moderate Buy” from the...
Mellstroy Net Worth: Controversies, Bans, and Scandals
Andrey Aleksandrovich Burim, known by his stage name, Mellstroy, is a European trash streamer. A controversial YouTuber, he gained popularity...
Lam Research Co. (NASDAQ:LRCX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Lam Research Co. (NASDAQ:LRCX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the nineteen brokerages...